Neurogene Inc.
NGNE
$15.00
$1.9715.12%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -176.03% | 40.32% | 52.54% | 30.71% | -384.82% |
| Gross Profit | 176.03% | -40.32% | -43.58% | -30.71% | 384.82% |
| SG&A Expenses | 141.86% | 63.16% | 133.63% | 90.33% | 30.38% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 46.69% | 45.74% | 67.19% | 43.30% | 13.78% |
| Operating Income | -46.69% | -45.74% | -59.84% | -43.30% | -13.78% |
| Income Before Tax | -918.88% | -38.69% | -55.92% | -37.98% | 119.44% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -918.88% | -38.69% | -55.92% | -37.98% | 119.44% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -918.88% | -38.69% | -55.92% | -37.98% | 119.44% |
| EBIT | -46.69% | -45.74% | -59.84% | -43.30% | -13.78% |
| EBITDA | -49.69% | -48.52% | -64.08% | -46.14% | -15.46% |
| EPS Basic | -101.23% | 96.35% | 95.91% | 96.46% | 3,864.26% |
| Normalized Basic EPS | 95.36% | 96.35% | 95.91% | 96.48% | -904.54% |
| EPS Diluted | -133.21% | 96.35% | 95.91% | 96.46% | 239.85% |
| Normalized Diluted EPS | -24.75% | 96.35% | 95.91% | 96.48% | 62.67% |
| Average Basic Shares Outstanding | 2,927.90% | 3,698.66% | 3,711.36% | 3,798.45% | -88.65% |
| Average Diluted Shares Outstanding | 12.52% | 3,698.66% | 3,711.36% | 3,798.45% | 205.40% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |